TheraVet: new commercial launch, share price rises
The veterinary biotechnology company explains that the product, called 'Biocera-Vet Combo-Clean', delivers a high concentration of antibiotics locally, while ensuring the stability of the system thanks to its mechanical strength.
Bone infections are often a major problem in orthopedic surgery, and can occur in up to 5% of operations, explains the Walloon company in a press release.
The bone substitute - which can be mixed with the seven most commonly used antibiotics for bone infections - has a long-lasting action of up to 30 days.
This launch - which reinforces the 'Biocera-Vet' range - was well received on the stock market, with TheraVet shares gaining over 4% in late morning trading. The share is still down 13% since the start of the year.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction